Same but different? A thematic analysis on adalimumab biosimilar switching among patients with juvenile idiopathic arthritis

Abstract Background Biologic medications have dramatically enhanced the treatment of many chronic paediatric inflammatory conditions. Their high cost is a factor that prohibits their broader use. Cheaper generic versions, or biosimilars, are increasingly being used. Healthcare services are switching...

Full description

Bibliographic Details
Main Authors: William D. Renton, Helen Leveret, Catherine Guly, Heather Smee, Jamie Leveret, Athimalaipet V. Ramanan
Format: Article
Language:English
Published: BMC 2019-10-01
Series:Pediatric Rheumatology Online Journal
Subjects:
Online Access:http://link.springer.com/article/10.1186/s12969-019-0366-x